Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.51 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 11/20 | 0.44 |
| ▸ | CALCR | P30988 | 11/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974251 | 0.88 | CAPN1 (0.53) | CAPN1RAMP3CALCRNTSR1CTSB | |
| SCHEMBL30420836 | 0.86 | NAA50 (0.50) | NAA50RAMP3CALCRNTSR1GRB2 | |
| SCHEMBL29477050 | 0.86 | CAPN1 (0.44) | CAPN1NAA50NTSR1CTSB | |
| SCHEMBL30420753 | 0.83 | GRB2 (0.47) | CAPN1NAA50RAMP3CALCRNTSR1 | |
| SCHEMBL29568938 | 0.81 | CTSL (0.45) | RAMP3CALCRGRB2 | |
| SCHEMBL29678077 | 0.80 | CAPN1 (0.46) | CAPN1RAMP3CALCR | |
| SCHEMBL31031538 | 0.80 | CAPN1 (0.47) | CAPN1CTSBGRB2 | |
| SCHEMBL31276263 | 0.80 | CAPN1 (0.51) | CAPN1NTSR1 | |
| SCHEMBL29565355 | 0.80 | NAA50 (0.42) | NAA50GRB2 | |
| SCHEMBL30420364 | 0.80 | NAA50 (0.49) | NAA50RAMP3CALCRGRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | TORQUE THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-114354558-A | Ratio type fluorescent nano probe, preparation method and method for quantitatively detecting activity of matrix metalloproteinase-7 | 中国科学院长春应用化学研究所 | 2022-04-15 | — | — | CN | disclosed |
| EP-3320923-B1 | FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | CD4, ICOS, IL2 | CAPN1 2457/4885NAA50 4549/4885RAMP3 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.